Telaprevir

Target: This ligand targets hepatitis C virus NS3/4A serine protease in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for hepatitis C virus NS3/4A serine protease. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings hepatitis C virus NS3/4A serine protease into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• Hepatoprotease Degrader Design: Telaprevir can serve as a protease-binding ligand to build PROTACs aimed at degrading target serine proteases involved in viral replication. By conjugating telaprevir-derived binding motifs to an E3 ligase recruiter, researchers can test whether ternary complex formation drives ubiquitination and proteasome-dependent removal of the protease in cellular degradation assays.

• Protease-Dependent Pathway Probing: Telaprevir-based PROTACs enable mechanistic studies of how protease activity controls downstream signaling and substrate processing. Researchers can compare degradation versus inhibition by measuring target protein turnover, ubiquitin engagement, and functional readouts such as substrate cleavage, thereby distinguishing catalytic blockade from degradation-driven pathway suppression.

• E3 Ligase Recruitment Optimization: Telaprevir can be repurposed to explore PROTAC architecture and E3 ligase selection. Systematic variation of linker length, attachment site, and recruiter identity can be used to maximize ternary complex stability and degradation potency, using quantitative immunoblotting and proteomics to map degradation kinetics and off-target degradation profiles.

• Target Engagement and Selectivity Mapping: Telaprevir-containing PROTACs can be used to validate target engagement through competition and washout experiments, then assess selectivity by profiling global protein changes. These studies help determine whether telaprevir’s binding mode supports efficient ubiquitination and selective proteasomal degradation under conditions relevant to PROTAC screening workflows.

Telaprevir is a NS3/4A protease ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Telaprevir is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; macrocyclic or peptidomimetic scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.